We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01522872
Recruitment Status : Active, not recruiting
First Posted : February 1, 2012
Last Update Posted : June 2, 2016
Information provided by (Responsible Party):
Threshold Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : September 2016
  Estimated Study Completion Date : September 2017